When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers ...

Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

COPENHAGEN - The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's ...

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

President-elect Donald Trump wants to buy the territory from Denmark, which says it’s not for sale. DealBook asked experts ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.